Kensey Nash sees broad application for biomaterials
This article was originally published in Clinica
Executive Summary
Kensey Nash has maintained a compound annual growth rate of 60% since its IPO in 1995, Joe Kauffmann, president and CEO of the company, told a recent UBS Warburg Global Life Sciences conference in New York. Kensey Nash is a small company developing biomaterials for a number of applications, from wound closure and drug delivery to orthopaedics, focussing on markets with a total potential of over $2 billion.